 |
12 Diseases |  |
1 Trial |
|
1 Trial |  |
240 News |  |
| 123» |
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei, Onbrez (indacaterol) / Novartis
Journal: The effect of lung emptying before the inhalation of aerosol drugs on drug deposition in the respiratory system. (Pubmed Central) - Jul 5, 2023
For drugs with negative correlation of lung dose with flow rate (all the studied drugs except the above two) lung emptying caused increased (Foster
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion date, Trial primary completion date: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma (clinicaltrials.gov) - May 22, 2023
P2, N=42, Recruiting, Sponsor: Novartis Pharmaceuticals
For drugs with negative correlation of lung dose with flow rate (all the studied drugs except the above two) lung emptying caused increased (Foster Trial completion date: Feb 2024 --> May 2025 | Trial primary completion date: Feb 2024 --> May 2025
- || Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment open: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma (clinicaltrials.gov) - Sep 26, 2022
P2, N=36, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Feb 2024 --> May 2025 | Trial primary completion date: Feb 2024 --> May 2025 Not yet recruiting --> Recruiting
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Rhinosporidium seebri .. got the similar slide in my MD exit examination (Twitter) - Aug 6, 2022
- || Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P2 trial: Pharmacokinetics, pharmacodynamics, safety and tolerability of glycopyrronium (bromide) in children (6 to less than 12 years) with asthma. Farmacocinética, farmacodinámica, seguridad y tolerabilidad de bromuro de glicopirronio en niños con asma (de 6 a menos de 12 años de edad). (EUDRACT) - Jun 24, 2022
P2, N=42, Ongoing, Sponsor: Novartis Farmacéutica, S.A.
- || Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P2 trial: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma (clinicaltrials.gov) - Feb 2, 2022
P2, N=36, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- || Onbrez (indacaterol) / Novartis
Clinical, Journal: Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients. (Pubmed Central) - May 27, 2021
Mean values and distributions of the deposited lung doses proved to be both drug and device specific, yielding 24.2 (±7.8), 22.6 (±3.6), 34.2 (±4.8) and 23.9 (±5.4) % values for Symbicort®, Onbrez®, Seebri® and Bretaris®, respectively...A more powerful inhalation significantly increases the lung dose for the drug emitted by Turbuhaler®, while long breath-hold is likely to yield significantly higher deposition for drugs emitted by Breezhaler® and Genuair®. Lung doses of two different drugs dispensed in the same inhaler can be significantly different.
- | Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Journal: Validation of a sensitive and specific LC-MS/MS Method and application to evaluate the systemic exposure and bioavailability of glycopyrrolate via different drug delivery approaches/devices. (Pubmed Central) - Apr 1, 2021
By comparing to the intravenous (IV) administration, it was found respective bioavailabilities of ~15% for GLY/Magnair and ~22% for Seebri Breezhaler. The bioanalytical reliability was also demonstrated by satisfactory incurred sample reanalysis performance.
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Journal: Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine. (Pubmed Central) - Mar 13, 2021
The bioanalytical reliability was also demonstrated by satisfactory incurred sample reanalysis performance. Muscarinic inhibition of salivation with GPB did not significantly reduce the uptake of PSMA-ligands or radioiodine in salivary glands, and can be dismissed as a potential strategy to reduce toxicity from radionuclide therapies.
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Journal: Expanded table: Correct use of inhalers for asthma. (Pubmed Central) - Jan 26, 2021
Muscarinic inhibition of salivation with GPB did not significantly reduce the uptake of PSMA-ligands or radioiodine in salivary glands, and can be dismissed as a potential strategy to reduce toxicity from radionuclide therapies. No abstract available
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei, Onbrez (indacaterol) / Novartis
[VIRTUAL] A Prospective, Observational Study to Evaluate Effectiveness and Safety of Fixed Dose Combination of Indacaterol Maleate 110 µg + Glycopyrronium Bromide 50 µg (IND/GLY 110/50 µg) in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients. (E-POSTER GALLERY) - Jan 24, 2021 - Abstract #NAPCON2020NAPCON_1088;
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] Debate on COPD - II Glycopyrronium bromide versus tiotropium bromide : which to use as a long-acting muscarinic antagonist for the treatment of obstructive airways disease ? Tiotropium. (HALL - D) - Jan 11, 2021 - Abstract #NAPCON2020NAPCON_648;
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] Debate on COPD - II Glycopyrronium bromide versus tiotropium bromide : which to use as a long-acting muscarinic antagonist for the treatment of obstructive airways disease ? Glycopyrronium . (HALL - D) - Jan 11, 2021 - Abstract #NAPCON2020NAPCON_647;
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Journal: Drugs for COPD. (Pubmed Central) - Dec 30, 2020
No abstract available No abstract available
- || Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Clinical, Journal: A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder. (Pubmed Central) - Dec 18, 2020
Determining the dose-response profile and washout period of scopolamine's antidepressant effect will also provide important information for designing and conducting crossover trials. The use of an active placebo is important to reduce potentially confounding expectancy effects.
- |||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Become part of the dry eye digital dialogue with Alcon by going to https://t.co/w0j9ck6jbn to register! #Ad #Alcon #SystaneiLux #Expandyourpractice #MGD #RootCause #DryEye #iluviLux #SeeBrilliantly #DEEP #optometry #ophthalmology #innovation (Twitter) - Dec 7, 2020
- || Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Clinical, Journal: Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry. (Pubmed Central) - Nov 21, 2020
TBR is still underused in severe asthma in a real-life setting, while a relevant proportion of patients are treated with other LAMA that are not approved for severe asthma treatment. Patients taking LAMA have features characteristic of even more severe asthma.
- |||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Become part of the dry eye digital dialogue with Alcon by going to https://t.co/w0j9ck6jbn to register! #Ad #Alcon, #SystaneiLux, #Expandyourpractice, #MGD, #RootCause, #DryEye, #iluviLux, #SeeBrilliantly, #DEEP #optometry #ophthalmology (Twitter) - Nov 11, 2020
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] Topical administration of 1% glycopyrronium bromide (GPB) cream is efficient and safe in treatment of primary axillary hyperhidrosis: A randomized placebo-controlled trial () - Oct 20, 2020 - Abstract #EADV2020EADV_2977;
- || Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Clinical, PK/PD data, Journal: Pharmacokinetics, pharmacodynamics and safety of a novel extrafine BDP/FF/GB combination delivered via metered-dose inhaler in healthy Chinese subjects. (Pubmed Central) - Oct 16, 2020
BDP/FF/GB pMDI was safe and well tolerated in healthy Chinese subjects. The PK profiles were comparable to previously published data from Western European healthy Caucasian subjects.
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] ETHNIC SENSITIVITY STUDY OF THE EXTRA-FINE SINGLE-INHALER TRIPLE THERAPY BECLOMETHASONE DIPROPIONATE/FORMOTEROL FUMARATE/GLYCOPYRRONIUM BROMIDE (BDP/FF/GB) PRESSURISED METERED DOSE INHALER (PMDI) IN HEALTHY JAPANESE AND CAUCASIAN SUBJECTS () - Oct 12, 2020 - Abstract #CHEST2020CHEST_2233;
These results are in line with available literature on exposure to these drugs in Japanese subjects. CLINICAL IMPLICATIONS: No dose adjustments in Japanese are deemed necessary for BDP/FF/GB pMDI.
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei, Onbrez (indacaterol) / Novartis
[VIRTUAL] Cost-Utility Analysis of Fixed Dose Combination (FDC) of Indacaterol Acetate (IND) Glycopyrronium Bromide (GLY) and Mometasone Furoate (MF) As a Maintenance Treatment in Adult Asthma Patients not Adequately Controlled with a Maintenance Com ... () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_691;
ICUR results of €14,088. At a threshold of €20,000 per QALY, IND/GLY/MF has nearly 100% probability of being cost-effective.CONCLUSIONS : The results indicate that IND/GLY/MF is cost-effective among the considered comparisons in a representative cohort of adult asthma patients in Italy.
- Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] Cost-Effectiveness of Once-Daily Single-Inhaler Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_204;
At a threshold of €20,000 per QALY, IND/GLY/MF has nearly 100% probability of being cost-effective.CONCLUSIONS : The results indicate that IND/GLY/MF is cost-effective among the considered comparisons in a representative cohort of adult asthma patients in Italy. At a willingness-to-pay threshold of $50,000/QALY, treatment with IND/GLY/MF is cost-effective in patients with uncontrolled moderate-to-severe asthma compared with SAL/FLU+Tio or SAL/FLU from a Canadian health care payer perspective.
- Veramyst (fluticasone furoate nasal spray) / GSK, Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] IMPACT of Health Technology Assessment (HTA) Recommendations on the Use of Fixed-Dose Combination (FDC) Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_195;
Initiatives aimed at restricting the use of FDC triple therapy leads to lower than average prescribing rates and potentially more appropriate use. It is essential for payers to assess the range of factors, including the risks and benefits of triple FDCs, and consider which restrictions would ensure the most efficient use of limited healthcare resources.
- |||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Become part of the dry eye digital dialogue with Alcon by going to https://t.co/VsPTfmQs2y to register! #Ad #Alcon #SystaneiLUX #Expandyourpractice #MGD #RootCause #DryEye #SeeBrilliantly #DEEP #optometry #ophthalmology #dryeye #innovation (Twitter) - Sep 14, 2020
- |||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Become part of the dry eye digital dialogue with Alcon by going to https://t.co/cptyDP5Xcd to register! #Ad #Alcon #SystaneiLUX #Expandyourpractice #MGD #RootCause #DryEye #SeeBrilliantly #DEEP #optometry #ophthalmology (Twitter) - Sep 2, 2020
- |||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Quench the symptoms of aqueous deficient #dryeye with SYSTANE® HYDRATION PF with HydroBoost Technology1 #Ad #optometry #ophthalmology #Alcon #seebrilliantly #systane https://t.co/aj0T0olGoI (Twitter) - Aug 26, 2020
- |||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
TONIGHT! Become part of the dry eye digital dialogue with Alcon by going to https://t.co/rVHoiFVv2k to register! #Ad #Alcon #Expandyourpractice #MGD #optometry #ophthalmology #RootCause #DryEye #SeeBrilliantly (Twitter) - Jul 21, 2020
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei, Onbrez (indacaterol) / Novartis
[VIRTUAL] Numerical simulation of the effect of inhalation parameters and disease severity on the deposition of dry powder aerosol drugs in COPD patients (Pre-congress content) - Jul 15, 2020 - Abstract #ERS2020ERS_3175;
1. Individual lung doses in case of Symbicort® Turbuhaler® (upper left), Onbrez® Breezhaler® (upper right), Seebri® Breezhaler® (lower left) and Bretaris® Genuair® (lower right) aerosol drugs.
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] Comparison of a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) formulation of extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in patients with COPD: The TRI-D study. (Pre-congress content) - Jul 15, 2020 - Abstract #ERS2020ERS_1630;
Individual lung doses in case of Symbicort® Turbuhaler® (upper left), Onbrez® Breezhaler® (upper right), Seebri® Breezhaler® (lower left) and Bretaris® Genuair® (lower right) aerosol drugs. DPI and pMDI formulations of extra fine BDP/FF/GB demonstrated similar efficacy and safety in patients with COPD supporting the new DPI formulation as a valid option for both patient and physician.
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] Effect of triple therapy with extra-fine BDP/FF/GB pMDI during seasonal peaks of asthma exacerbations. A post-hoc analysis of the TRIMARAN and TRIGGER studies (Pre-congress content) - Jul 15, 2020 - Abstract #ERS2020ERS_712;
AIMS AND OBJECTIVES: We evaluated the effect of extra-fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) pressurized metered dose inhaler (pMDI) on asthma exacerbation rates during the four seasons... Treatment with extra-fine BDP/FF/GB reduces seasonal peaks of asthma exacerbations in adults with asthma uncontrolled on BDP/FF, particularly in those with PAL.
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] Possible Low-Value Medication Use by Persons with Idiopathic Pulmonary Fibrosis (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_6452;
One hundred seventeen (117, 28%) persons were first treated with a proton pump inhibitor following IPF diagnosis. Two hundred eleven (211, 50%) persons used a SABA.
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei, Onbrez (indacaterol) / Novartis
[VIRTUAL] Once-Daily Indacaterol Acetate, Glycopyrronium Bromide, and Mometasone Furoate as a Fixed-Dose Combination in Japanese Patients with Inadequately Controlled Asthma: A Multicenter, 52-Week Safety Study (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_3866;
P3
CONCLUSIONS : Once-daily IND/GLY/MF high-dose was well-tolerated in Japanese patients with inadequately controlled asthma with no new or unexpected safety signals observed. Sustained and clinically meaningful improvements were observed in lung function and asthma control throughout the study.
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] Effect of Medium ICS Dose Fixed Combination Extra Fine Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide (BDP/FF/GB) pMDI on Lung Function in Asthmatics with Persistent Airflow Limitation (PAL): A Post-Hoc Analysis of the Trimaran Study (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_3863;
In patients with asthma uncontrolled on medium ICS dose ICS/LABA, extra fine triple therapy with medium ICS dose BDP/FF/GB significantly improves lung function vs BDP/FF. Consistent with data from other studies, a more pronounced bronchodilator effect is seen in the subset of patients with PAL.
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] Effect of High ICS Dose Fixed Combination Extra Fine Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide (BDP/FF/GB) on Lung Function in Asthmatics with Persistent Airflow Limitation (PAL): A Post-Hoc Analysis of the TRIGGER Study (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_3859;
In patients with asthma uncontrolled on high ICS dose ICS/LABA, triple therapy with high ICS dose extra fine BDP/FF/GB significantly improves lung function vs BDP/FF. Consistent with data from other studies, a more pronounced bronchodilator effect is seen in the subset of patients with PAL.
- |||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Become part of the dry eye digital dialogue with Alcon by going to https://t.co/D2IkDm6u19 to register! #Ad #Alcon #Expandyourpractice #MGD #RootCause #DryEye #SeeBrilliantly (Twitter) - Jun 18, 2020
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Journal: Synthesis of C-14 labeled Rac-(3R,2S)-Glycopyrronium Bromide. (Pubmed Central) - Jun 3, 2020
During the synthesis, an unexpected decarboxylation of phenylglyoxylate resulted in the loss of much of the radiolabeled compound. Chiral chromatography was utilized to isolate and deliver the proper pair of enantiomers as [ C]-1.
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] Assessment of efficacy and safety of topical administration of 1% glycopyrronium bromide (GPB) in patients with primary axillary hyperhidrosis () - May 27, 2020 - Abstract #AADVMX2020AAD-VMX_112;
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Journal: Abnormal Presentation of Hypoxic Ischemic Encephalopathy Attributed to Polysubstance Exposure. (Pubmed Central) - Apr 26, 2020
Clonidine was used to control the NAS symptoms, ranitidine was used to treat the gastroesophageal reflux, and glycopyrronium bromide was used for the neonate's excessive secretions. After delivery, the patient was placed on a nasal noninvasive cannula for respiratory distress and was transferred to a different hospital for treatment of the more serious comorbid conditions.
- || Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Clinical, Review, Journal: Pharmacology, toxicology and clinical safety of glycopyrrolate. (Pubmed Central) - Apr 14, 2020
More recently, topical formulations of glycopyrrolate (GPB, also known as glycopyrronium bromide) have gained interest as a treatment option for excessive sweating (hyperhidrosis)...The information on the nonclinical and clinical safety profile of glycopyrronium supporting various therapeutically approved uses has been obtained from published literature, our own data as well as summary documents issued by regulatory bodies. Collectively, these data support the conclusion that the benefits of glycopyrronium generally outweigh the risks in chronic use indications that require muscarinic receptor antagonism to provide therapeutic effects.
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Possible Low-Value Medication Use by Persons with Idiopathic Pulmonary Fibrosis (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area K) - Mar 15, 2020 - Abstract #ATS2020ATS_9137;
One hundred seventeen (117, 28%) persons were first treated with a proton pump inhibitor following IPF diagnosis. Two hundred eleven (211, 50%) persons used a SABA.
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei, Onbrez (indacaterol) / Novartis
Once-Daily Indacaterol Acetate, Glycopyrronium Bromide, and Mometasone Furoate as a Fixed-Dose Combination in Japanese Patients with Inadequately Controlled Asthma: A Multicenter, 52-Week Safety Study (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area C) - Mar 15, 2020 - Abstract #ATS2020ATS_6273;
P3
Once-daily IND/GLY/MF high-dose was well-tolerated in Japanese patients with inadequately controlled asthma with no new or unexpected safety signals observed. Sustained and clinically meaningful improvements were observed in lung function and asthma control throughout the study.
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Effect of Medium ICS Dose Fixed Combination Extra Fine Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide (BDP/FF/GB) pMDI on Lung Function in Asthmatics with Persistent Airflow Limitation (PAL): A Post-Hoc Analysis of the Trimaran Study (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area C) - Mar 15, 2020 - Abstract #ATS2020ATS_6270;
In patients with asthma uncontrolled on medium ICS dose ICS/LABA, extra fine triple therapy with medium ICS dose BDP/FF/GB significantly improves lung function vs BDP/FF. Consistent with data from other studies, a more pronounced bronchodilator effect is seen in the subset of patients with PAL.
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Effect of High ICS Dose Fixed Combination Extra Fine Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide (BDP/FF/GB) on Lung Function in Asthmatics with Persistent Airflow Limitation (PAL): A Post-Hoc Analysis of the TRIGGER Study (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area C) - Mar 15, 2020 - Abstract #ATS2020ATS_6266;
In patients with asthma uncontrolled on high ICS dose ICS/LABA, triple therapy with high ICS dose extra fine BDP/FF/GB significantly improves lung function vs BDP/FF. Consistent with data from other studies, a more pronounced bronchodilator effect is seen in the subset of patients with PAL.
- || Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Clinical, Journal: Assessment of patient-reported outcomes by questionnaires in patients with Moderate and severe chronic obstructive pulmonary disease treated with glycopyrroniUm in the reaL lifE setTing in Hungary (AMULET) (Pubmed Central) - Mar 3, 2020
Aim and The aim of the study was to evaluate patient-reported outcomes with guideline-suggested questionnaires (CCQ, CAT, mMRC, EQ-5D-5L) in patients treated with glycopyrronium-bromide (therapy naïve, add-on combination or switch from another therapy) in the real life setting during 16 weeks treatment...Orv Hetil. 2020; 161(8): 295-305.
- | Bevespi Aerosphere (formoterol/glycopyrrolate) / AstraZeneca, Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Review, Journal: Glycopyrronium/Formoterol: A Review in COPD. (Pubmed Central) - Jan 30, 2020
Glycopyrronium/formoterol was generally well tolerated in patients with moderate to very severe COPD, with most adverse events (AEs) being of mild or moderate severity. Thus, glycopyrronium/formoterol pMDI formulated using co-suspension delivery technology is a useful new addition that extends treatment options for patients with COPD.
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Journal: HPTLC Method for Determination of R, R-Glycopyrronium Bromide and its Related Impurities. (Pubmed Central) - Jan 27, 2020
The method was used to investigate impurity profile of GLY in drug substance and drug product and could be applied in routine analysis of the drug. Comparison between the developed method and the reported method revealed no statistical difference.
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Clinical, Journal: Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease. (Pubmed Central) - Jan 8, 2020
P1
Slightly higher number of subjects reported adverse events with GLY/DPI than with GLY/eFlow. Nebulized GLY may offer an effective alternative to patients with COPD not adequately treated with other devices.
- Seebri (glycopyrronium bromide) / Novartis, Vectura, Sosei
Characteristics of prominent response to triple therapy in patients with asthma uncontrolled on ICS/LABA: A stratified analysis of the TRIMARAN and TRIGGER studies (9D) - Aug 26, 2019 - Abstract #ERS2019ERS_6168;
Triple therapy with extrafine BDP/FF/GB significantly reduces severe exacerbations in asthmatics uncontrolled on ICS/LABA. Six easily identifiable traits are associated with the most prominent response to treatment and may help treatment escalation decision at the point of care.
- Seebri (glycopyrronium bromide) / Novartis, Vectura, Sosei
Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study (6F) - Aug 26, 2019 - Abstract #ERS2019ERS_5632;
INTRODUCTION: Persistent airflow limitation (PAL) may predict a positive clinical response to add-on long-acting muscarinic antagonist (LAMA) in asthmatics on inhaled corticosteroids and long-acting β2-receptor agonists (ICS/LABA) OBJECTIVES: We evaluated the effect of extrafine HS beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) on asthma exacerbations in a subset of patients with PAL TRIGGER was a phase III randomized, parallel group trial comparing 52-week treatment with BDP/FF/GB 800/24/50 µg/d to BDP/FF 800/24 µg/d via pressurized metered dose inhalers (pMDI) and open-label treatment consisting of BDP/FF plus tiotropium Respimat® 5 μg/d (TioR) in adult patients with uncontrolled asthma on high-dose ICS/LABA and a history of exacerbation in the past year... PAL is associated with a greater response to triple therapy with extrafine HS BDP/FF/GB in patients with asthma uncontrolled on high dose ICS/LABA